HIV-1-infected patients from the French National Observatory experiencing virological failure while receiving enfuvirtide

Journal of Antimicrobial Chemotherapy

Volumn 62, Issue 3, 2008, Pages 451-455

  Descamps, Diane ^a,b,c   Assoumou, Lambert ^c,d   Masquelier, Bernard ^e   Marcelin, Anne Geneviève ^d,f   Saidi, Souhila ^c,d   Tamalet, Catherine ^g   Cottalorda, Jacqueline ^h   Plantier, Jean Christophe ⁱ   Montes, Brigitte ^j   Izopet, Jacques ^k   Peytavin, Gilles ^a   Yerly, Sabine ^l   Schneider, Véronique ^m   Delaugerre, Constance ^b,n   Ferré, Virginie ^o   Ruffault, Annick ^p   Pallier, Coralie ^q   Morand Joubert, Laurence ^d,r   Chaix, Marie Laure ^b,n   Calvez, Vincent ^d,f   Brun Vézinet, Françoise ^a,b,c   Costagliola, Dominique ^c,d,f   more..

^a BICHAT HOSPITAL   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSERM   (France)

^d SORBONNE UNIVERSITÉ   (France)

^e BORDEAUX UNIVERSITY HOSPITAL   (France)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^g TIMONE HOSPITAL   (France)

^h UNIVERSITY HOSPITAL OF NICE   (France)

ⁱ UNIVERSITÉ DE ROUEN   (France)

^j MONTPELLIER UNIVERSITY HOSPITAL   (France)

^k TOULOUSE UNIVERSITY HOSPITAL   (France)

^l GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^m HÔPITAL TENON   (France)

ⁿ HÔPITAL NECKER ENFANTS MALADES   (France)

^o NANTES UNIVERSITY HOSPITAL   (France)

^p RENNES UNIVERSITY HOSPITAL   (France)

^q BICÊTRE HOSPITAL   (France)

^r HÔPITAL SAINT ANTOINE   (France)

more..

Author keywords

gp41; HIV drug resistance; Resistance mutations; T 20

Indexed keywords

ANTIRETROVIRUS AGENT; ENFUVIRTIDE; GLYCOPROTEIN GP 41; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; ARTICLE; BLOOD SAMPLING; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CODON; DRUG TREATMENT FAILURE; FOLLOW UP; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NONHUMAN; SALVAGE THERAPY; VIRUS LOAD; VIRUS MUTATION; VIRUS RESISTANCE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AMINO ACID SUBSTITUTION; CD4 LYMPHOCYTE COUNT; FEMALE; FRANCE; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; MUTATION, MISSENSE; PEPTIDE FRAGMENTS; RNA, VIRAL; SALVAGE THERAPY; SEQUENCE ANALYSIS, DNA; TREATMENT OUTCOME; VIRAL LOAD;

EID: 49749114865     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn225     Document Type: Article

References (10)

1. Johnson VA, Brun-Vezinet F, Clotet B et al. Update of the drug resistance mutations in HIV-1: Fall 2006. Top HIV Med 2006; 14 125-30.
2. Peuchant O, Capdepont S, Ragnaud JM et al. Primary resistance to enfuvirtide (T20) in recently HIV-1 infected, antiretroviral-naive patients from the ANRS Aquitaine Cohort. Antivir Ther 2007; 12 559-62.
3. Carmona R, Perez-Alvarez L, Munoz M et al. Natural resistance-associated mutations to enfuvirtide (T20) and polymorphisms in the gp41 region of different HIV-1 genetic forms from T20 naive patients. J Clin Virol 2005; 32: 248-53.
4. Chinnadurai R, Munch J, Kirchhoff F. Effect of naturally-occurring gp41 HR1 variations on susceptibility of HIV-1 to fusion inhibitors. AIDS 2005; 19: 1401-5.
5. Aquaro S, D'Arrigo R, Svicher V et al. Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment. J Antimicrob Chemother 2006; 58: 714-22.
6. Cabrera C, Marfil S, Garcia E et al. Genetic evolution of gp41 reveals a highly exclusive relationship between codons 36, 38 and 43 in gp41 under long-term enfuvirtide-containing salvage regimen. AIDS 2006; 20: 2075-80.
7. Marcelin AG, Reynes J, Yerly S et al. Characterization of genotypic determinants in HR-1 and HR-2 gp41 domains in individuals with persistent HIV viraemia under T-20. AIDS 2004; 18: 1340-2.
8. Su C, Melby T, DeMasi R et al. Genotypic changes in human immunodeficiency virus type 1 envelope glycoproteins on treatment with the fusion inhibitor enfuvirtide and their influence on changes in drug susceptibility in vitro. J Clin Virol 2006; 36: 249-57.
9. Loutfy MR, Raboud JM, Montaner JS et al. Assay of HIV gp41 amino acid sequence to identify baseline variation and mutation development in patients with virologic failure on enfuvirtide. Antiviral Res 2007; 75: 58-63.
10. Svicher V, Aquaro S, D'Arrigo R et al. Specific T20-selected mutational pathways in gp41 are significantly correlated with a gain of CD4 T-cell count despite virological failure. In: Abstracts of the 16th International HIV Drug Resistance Workshop: Basic Principles and Clinical Implications, Barbados, West Indies 2007. Antivir Ther 2007; Suppl 1: S115.